Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Neurological disorders stories

Oct 30, 2026

EMA reviews Lundbeck's Deanxit after reports of serious neurological side effects

The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.

Oct 30, 2026·2 sources
00
Oct 29, 2026

University of Eastern Finland identifies vitamin transporter protein for brain drug delivery

Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.

Oct 29, 2026·4 sources
00
Oct 28, 2026

Mayo Clinic study finds deep brain stimulation produces measurable brain changes within 18 minutes in epilepsy patients

Mayo Clinic researchers detected measurable brain changes within 18 minutes of deep brain stimulation in patients with drug-resistant epilepsy, a finding that could help clinicians personalize treatment settings without waiting months to assess effectiveness.

Oct 28, 2026·2 sources
00
Oct 23, 2026

Novartis multiple sclerosis drug remibrutinib shows weaker-than-expected relapse reduction

Novartis' oral multiple sclerosis drug remibrutinib meaningfully reduced relapses in patients but showed less efficacy than expected in phase 3 trials, potentially giving competitor Roche an advantage with its rival treatment.

Oct 23, 2026·4 sources
00

Christina Applegate reveals multiple sclerosis misdiagnosis after five years

Actor Christina Applegate disclosed she was misdiagnosed with multiple sclerosis five years after her 2021 diagnosis, highlighting challenges in MS diagnosis that experts say are common in neurology.

Oct 23, 2026·3 sources
00
Oct 22, 2026

Rituximab linked to increased inflammatory bowel disease risk in multiple sclerosis patients

A study published in JAMA Neurology found that multiple sclerosis patients treated with rituximab have an increased risk of developing inflammatory bowel disease, particularly Crohn's disease, though the absolute risk remains low. The research compared rituximab to other MS treatments.

Oct 22, 2026·2 sources
00
Oct 5, 2026

Shionogi to acquire IntraBio for $2 billion

Japanese pharmaceutical company Shionogi has agreed to acquire American biotech IntraBio for $2 billion, gaining global rights to Aqneursa, a treatment for rare neurological conditions.

Oct 5, 2026·3 sources
00
Sep 3, 2026

Ultragenyx's Angelman syndrome drug fails Phase 3 trial

Ultragenyx Pharmaceuticals' apazunersen did not meet the goals of its Phase 3 test in Angelman syndrome, a rare genetic neurological disorder with no FDA-approved therapies. The failure of what was once considered a potential blockbuster therapy is forcing Ultragenyx to examine significant cost cuts.

Sep 3, 2026·2 sources
00
Sep 1, 2026

Novartis pauses autoimmune cell therapy trials after three patient deaths

Novartis temporarily halted enrollment and treatment in eight clinical trials of an experimental CAR-T therapy for autoimmune and neurological disorders in late August after three patients died. Bristol Myers Squibb programs were also paused.

Sep 1, 2026·3 sources
00
Aug 26, 2026

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 10, 2026

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.

Aug 10, 2026·6 sources
00
Jul 28, 2026

Novel interventional approach shows success in treating hepatic myelopathy, rare liver disease complication

Researchers have developed a new interventional treatment for hepatic myelopathy, a rare neurological complication of chronic liver disease that previously could only be cured through liver transplantation.

Jul 28, 2026·1 source
00
Apr 22, 2026

Kyverna Therapeutics Plans FDA Submission for Stiff Person Syndrome Cell Therapy

Kyverna Therapeutics announced plans to submit its one-time CAR-T cell therapy for stiff person syndrome to the FDA after late-stage trial showed improvements in mobility and reduced disabilities in patients with the rare neurological disease.

Apr 22, 2026·1 source
00

Top claims

  • ▪Danish drugmaker H Lundbeck declined to comment on the European Medicines Agency's safety review of Deanxit.
  • ▪Belgium's medicines agency raised concerns about the long-term use of Deanxit, noting that flupentixol has been linked to potentially irreversible serious side effects.
  • ▪The European Medicines Agency's Pharmacovigilance Risk Assessment Committee will evaluate Deanxit data to decide whether to retain, amend, suspend, or revoke the drug's marketing authorization, with the review expected to conclude by March.

Subtopics

Drug Policy, Pricing & Approval7Clinical trials5Drug Approval and Clinical Trials5Drug development5Pharmaceutical Industry4Pharma3Autoimmune disease2Medical research2Neuroscience2Rare diseases2Rare genetic diseases2Adverse event reporting (FAERS)1Angelman syndrome1Anti-depressant1Anxiety and depression1Autoimmune disease treatments1Biologic therapies1Biomedical research1Biotech innovation1Biotechnology1Brain health1CAR T-cell therapy1Clinical evaluation1Clinical trial design1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories